WVP
TVRD

Worth Venture Partners’s Tvardi Therapeutics TVRD Stock Holding History

Worth Venture Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-89
Closed -$50K – 145
2017
Q2 		$50K Buy
+89
New +$56.5K 0.04% 96

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Worth Venture Partners's TVRD Position: Q3 2017 in Review

Worth Venture Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 89 shares — an estimated $50K sold.

Worth Venture Partners first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $50K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • Worth Venture Partners reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Worth Venture Partners sold 89 Tvardi Therapeutics shares in Q3 2017, an estimated $50K.
  • Worth Venture Partners first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
  • Worth Venture Partners's Tvardi Therapeutics position peaked at $50K in Q2 2017.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Worth Venture Partners's 13F filing for Q3 2017, filed 7 Nov 2017.